Other

Baxter International Inc.

Baxter Healthcare Sa

Baxter Aktiengesellschaft

Jane P Richards

Douglas L Looker

Heinz Redl

David Eugene Pereira

Kenneth E Burhop

David L Foster

Michael P Doyle

Sam L Helgerson

Izydor Z Apostol

Geoffrey F Lee

Walter Fuerst

Douglas D Lemon

Stephen P Trimble

Christopher B Glascock

Rudolf Kneidinger

Elisabeth M Inman

James C Hartman

Catalina Wong

Eric A Brucker

Edwin G Moore

Michael R Schick

Ton-That Hai

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Reduced side-effect hemoglobin compositions

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGFC-terminal domain fused to a wound-healing substance such as leptin.

Fibrin/fibrinogen-binding conjugate

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF C-terminal domain fused to a wound-healing substance such as leptin.

Growing community of inventors

Longmont, CO, United States of America

Jane P Richards